Hematology (all articles)
Single-arm phase 2 study | Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent alpha-thalassaemia or beta-thalassaemia.
18 Aug, 2022 | 12:40h | UTCSafety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link to abstract – $ for full-text)
Commentary: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (free registration required)
Guideline | Use of COVID-19 convalescent plasma.
17 Aug, 2022 | 14:28h | UTC
M-A | Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients.
15 Aug, 2022 | 12:27h | UTCRelated:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Review | Plasma exchange in the intensive care unit.
15 Aug, 2022 | 12:19h | UTCPlasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine
Commentary on Twitter
Therapeutic plasma exchange in #ICU
🟨 indications for urgent TPE
🟨 mechanisms, kinetics and therapeutic goals
🟨 diagnostic workup & monitoring
🟨 technical aspects
🟨 clinical response & complications
🟨 unanswered questions & research agenda#FOAMcc
📎 https://t.co/CojkcA81Dy pic.twitter.com/MsAdjgJhNL— Intensive Care Medicine (@yourICM) August 13, 2022
M-A | Interventions to reduce infections in patients with hematological malignancies.
15 Aug, 2022 | 11:51h | UTCCommentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC
Long-term results of a phase 2 RCT | Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma.
15 Aug, 2022 | 11:46h | UTCOriginal Study: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
Consensus Guidance | Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis.
12 Aug, 2022 | 14:54h | UTC
RCT | Low-dose Decitabine vs. low-dose Azacitidine in lower-risk myelodysplastic syndromes.
11 Aug, 2022 | 12:04h | UTCLow-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence
Commentary on Twitter
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. https://t.co/OSpNLzfiKW#MDS #LeuSM #CMML pic.twitter.com/BN1XAhfUBo
— NEJM Evidence (@NEJMEvidence) August 9, 2022
Single-arm phase 2 study | Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma.
9 Aug, 2022 | 12:22h | UTCLong-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
🙌 Combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with relapsed/refractory #MultipleMyeloma ➡️ https://t.co/TkPRcTKSxg #JCO #MMSM pic.twitter.com/0OZAJtTXF1
— Journal of Clinical Oncology (@JCO_ASCO) April 15, 2022
Guideline | Management of antithrombotic treatments in thrombocytopenic patients with cancer.
5 Aug, 2022 | 14:37h | UTC
Review | Thrombotic microangiopathy in children.
5 Aug, 2022 | 13:56h | UTCThrombotic microangiopathy in children – Pediatric Nephrology (if the link is paywalled, try this one)
Cohort Study | Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine.
3 Aug, 2022 | 13:53h | UTC
Commentary on Twitter
#OrigInvestigation: Reduction of acute chest syndrome incidence in children with sickle-cell disease following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in France. https://t.co/MuG6T0g5FU
— JAMA Network Open (@JAMANetworkOpen) August 2, 2022
Systematic Review | Stem cell transplantation for systemic sclerosis.
1 Aug, 2022 | 12:10h | UTCStem cell transplantation for systemic sclerosis – Cochrane Library
Summary: Stem cell transplantation for the treatment of systemic sclerosis – Cochrane Library
Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.
1 Aug, 2022 | 11:46h | UTC
Commentary on Twitter
🙌 Venetoclax plus gilteritinib yields modified composite complete response of 75% in FLT3-mutated relapsed/refractory #AcuteMyeloidLeukemia
Read in #JCO ➡️ https://t.co/L7wxJ63qv9 #AML #leusm @Daver_Leukemia @jaltmanmd pic.twitter.com/ksXw1DNMsE
— Journal of Clinical Oncology (@JCO_ASCO) July 29, 2022
RCT | Short vs. extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia.
27 Jul, 2022 | 12:17h | UTCShort versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary: Short-Course or Extended Antibiotics in Febrile Neutropenia? – Medscape (free registration required)
Commentary on Twitter
NEW online—Short-term is not inferior to extended carbapenem in patients with haematological malignancy and neutropenic fever of unknown origin, however, higher serious adverse events and mortality were noted in the short treatment group: the SHORT trial https://t.co/FOp1M3D6cL pic.twitter.com/6z5e8MSEgQ
— The Lancet Haematology (@TheLancetHaem) June 10, 2022
Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.
27 Jul, 2022 | 11:53h | UTCLong-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer
Commentaries:
CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay
Systematic Review | Antiplatelet agents for the treatment of deep venous thrombosis.
26 Jul, 2022 | 12:44h | UTCAntiplatelet agents for the treatment of deep venous thrombosis – Cochrane Library
Summary: Aspirin and similar drugs for the treatment of deep vein thrombosis (DVT) – Cochrane Library
RCT | Ticagrelor is ineffective for reducing vaso-occlusive crises in pediatric sickle cell disease.
25 Jul, 2022 | 12:50h | UTC
RCT | Enasidenib vs. conventional care in mutant-IDH2 relapsed/refractory acute myeloid leukemia.
22 Jul, 2022 | 11:31h | UTC
Single-arm phase 1–2 trial of AAVS3 gene therapy in patients with Hemophilia B.
21 Jul, 2022 | 13:23h | UTCPhase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Novel gene therapy could reduce bleeding risk for hemophilia patients – University College London
Commentary: Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants – AJMC
Commentary on Twitter
Nine of 10 patients with hemophilia B who received a liver-directed adeno-associated viral vector containing a hyperactive variant of factor IX maintained factor IX activity for up to 42 months. Thrombosis developed in 1 patient. https://t.co/yId8HWS1u2 pic.twitter.com/CdDeizSMK6
— NEJM (@NEJM) July 20, 2022
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
20 Jul, 2022 | 12:08h | UTCThe epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends – The Lancet Haematology (free registration required)
Commentary on Twitter (thread – click for more)
@CUHKMedicine: collaborative work with @APRU1997 colleagues published. @TheLancet Haematology: Epidemiological Landscape of Multiple Myeloma from Cancer Registry Analysis @CUHKGlobal pic.twitter.com/17tr2Z30Xh
— Wong Chi Sang Martin (@drwong_martin) July 14, 2022
Single-arm phase 2 study | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
20 Jul, 2022 | 11:37h | UTCSafety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
ELN International Recommendations for the diagnosis and management of acute myeloid leukemia in adults.
19 Jul, 2022 | 13:28h | UTC
Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.
19 Jul, 2022 | 13:00h | UTCLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)
Related:
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Lisocabtagene maraleucel as second-line therapy in adults with R/R large B-cell #lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study https://t.co/NwkfPmVHu0 #lymsm pic.twitter.com/jHj5rFadV2
— The Lancet Oncology (@TheLancetOncol) July 13, 2022
RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
19 Jul, 2022 | 12:57h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)